Addition Therapeutics, a UC‑Berkeley spinout, surfaced from stealth with more than $100 million in financing to back a new RNA‑based gene insertion approach (branded as PRINT in some coverage). The company announced experienced biotech executives on its leadership team and positioned the platform to address challenges in gene insertion for chronic and rare diseases. Investors and collaborators include academic founders and venture backers focused on enabling more precise, durable genetic medicine. Addition’s entrance underscores continuing investor appetite for novel delivery and insertion technologies that promise to overcome limitations of current gene‑therapy tools.